Pinz et al. evaluated a CD4-targeted CAR-T in ALL (Acute Lymphoblastic Leukemia) models, and they showed a better control with high doses of CAR-T (minimum 10 × 106 CAR-T per mouse) [52]. The gene discussed is CD4; the disease is acute lymphoblastic leukemia.